Literature DB >> 2706635

SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells.

H P Vollmers1, R O'Connor, J Müller, T Kirchner, H K Müller-Hermelink.   

Abstract

Human monoclonal antibodies were isolated from stomach carcinoma patients by the fusion of spleen and lymph node lymphocytes with the heteromyeloma line SPM4-0. Initial screening was carried out on autologous primary tumor cell cultures in an adhesion assay in order to select surface-reactive functional antibodies. This was followed by live cell immunoperoxidase staining assays. The human monoclonal antibody SC-1 was found to selectively react with cultured cells isolated from autologous and allogeneic stomach carcinoma patients, and with cryostat sections of the primary tumors. More extensive screening revealed that the antibody showed no reactivity with a wide range of tumor tissues and normal cells. Some reactivity was present on fetal tissues. SC-1 inhibits movement of the autologous tumor cells and identifies a protein with a molecular weight of 50,000. This study demonstrates that, with the use of selective screening assays on primary tumor material, it is possible to isolate antibodies which not only result from an immune response in the patient but also interfere with intercellular processes of tumor cells.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2706635

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Molecular analysis of rheumatoid factor (RF)-negative B cell hybridomas from rheumatoid synovial tissue: evidence for an antigen-induced stimulation with selection of high mutated IgVH and low mutated IgVL/lambda genes.

Authors:  V Krenn; A König; F Hensel; C Berek; M M Souto Carneiro; W Haedicke; Y Wang; H Vollmers; H K Müller-Hermelink
Journal:  Clin Exp Immunol       Date:  1999-01       Impact factor: 4.330

2.  High level expression of functional human IgMs in human PER.C6 cells.

Authors:  Anna Tchoudakova; Frank Hensel; Alec Murillo; Bernie Eng; Marketa Foley; Lakee Smith; Frank Schoenen; Antonia Hildebrand; Arndt-René Kelter; Leodevico L Ilag; H Peter Vollmers; Stephanie Brandlein; Jane McIninch; John Chon; Gene Lee; Marco Cacciuttolo
Journal:  MAbs       Date:  2009-03-24       Impact factor: 5.857

3.  Tumor-associated antigens recognized by human monoclonal antibodies.

Authors:  H R Chang; K Koda; M E McKnight; M C Glassy
Journal:  Ann Surg Oncol       Date:  1994-05       Impact factor: 5.344

4.  HAB-1, a new heteromyeloma for continuous production of human monoclonal antibodies.

Authors:  G Faller; H P Vollmers; I Weiglein; A Marx; C Zink; M Pfaff; H K Müller-Hermelink
Journal:  Br J Cancer       Date:  1990-10       Impact factor: 7.640

5.  Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1.

Authors:  Frank Hensel; Wolfgang Timmermann; Burkhard H A von Rahden; Andreas Rosenwald; Stephanie Brändlein; Bertram Illert
Journal:  Oncol Rep       Date:  2014-01-20       Impact factor: 3.906

6.  Antibody Binding Specificity for Kappa (Vκ) Light Chain-containing Human (IgM) Antibodies: Polysialic Acid (PSA) Attached to NCAM as a Case Study.

Authors:  Jens O Watzlawik; Robert J Kahoud; Bharath Wootla; Meghan M Painter; Arthur E Warrington; William A Carey; Moses Rodriguez
Journal:  J Vis Exp       Date:  2016-06-29       Impact factor: 1.355

7.  Use of a local immunotherapy as an adjunctive tool for the generation of human monoclonal antibodies from regional lymph nodes of colonic cancer patients.

Authors:  T Yagyu; T Monden; Y Tamaki; H Morimoto; T Takeda; T Kobayashi; T Shimano; H Murakami; T Mori
Journal:  Jpn J Cancer Res       Date:  1992-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.